Quantum Pharmaceuticals

Name

Quantum Pharmaceuticals

Website

https://q-pharm.com

Company type

Private

Founded year

2004

Headcount range

11–50 employees

Short description

Quantum Pharmaceuticals is a privately held drug discovery company headquartered in Moscow, Russian Federation, founded in 2004, operating with 11-50 employees under founder and CSO Peter Fedichev.

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand) (HDAGAEAB)

akta.pro secondary industry

Quantum Simulation (Physics/Chemistry/Materials) Research (HDAGAMAG)

Keywords

• Drug discovery services
• Pharmaceutical research
• Medicinal chemistry
• Small molecule therapeutics
• Preclinical development

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

Quantum Pharmaceuticals is a drug discovery company that conducts research and development of pharmaceutical compounds. Founded in 2004 and headquartered in Moscow, the firm maintains a small specialist team of 11-50 employees focused on the identification and development of small molecule therapeutics for pharmaceutical and biotechnology clients.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Direct peers

• Exscientia: AI-driven precision medicine and drug discovery company with a focus on small-molecule design and pharma partnerships. Comparable as a peer pursuing AI-enabled discovery and asset out-licensing.
• Atomwise: AI small-molecule discovery company using structure-based deep learning for hit identification and optimization. Comparable as a technology-platform peer focused on early-stage discovery collaborations with pharma.
• BenevolentAI: AI-driven drug discovery company combining knowledge graphs and ML to identify novel targets and molecules. Comparable as a peer using computational methods to generate differentiated pharma R&D assets.
• Insilico Medicine: AI-driven drug discovery company with end-to-end platforms from target identification to clinical-stage assets. Comparable as a technology-forward small-molecule discovery peer pursuing both internal pipeline and pharma partnerships.
• XtalPi: AI- and physics-based drug discovery company that uses computational modeling (including quantum-physics and crystal-structure prediction) to accelerate small-molecule R&D. Direct functional peer given the 'Quantum' framing of computational pharma R&D.
• Schrödinger: Public computational drug discovery platform combining physics-based simulation with ML for small-molecule discovery. Highly comparable as a similarly positioned 'computational/quantum-inspired' pharma R&D company pursuing asset development and platform partnerships.
• Recursion Pharmaceuticals: Tech-enabled drug discovery company using high-throughput biology and ML to build a broad pipeline. Comparable as a platform-driven discovery peer pursuing both internal assets and large-pharma collaborations.

Emerging players

• PhoreMost: UK-based small-molecule drug discovery company using a target-identification platform. Comparable as a similarly sized emerging discovery peer pursuing partnerships and asset development.
• Iambic Therapeutics: AI-driven drug discovery company combining physics-based simulation with ML to design differentiated small molecules. Comparable as an emerging peer pursuing platform-and-pipeline strategy in computational pharma.

Broad incumbents

• Isomorphic Labs: Alphabet-owned drug discovery company leveraging DeepMind's computational biology and protein-structure prediction capabilities. Comparable as a well-capitalized broad incumbent applying advanced computation (including quantum-relevant methods) to pharma R&D.

Market position

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quantum Pharmaceuticals